Bibliography
- Johnson AH, Peacock JL, Greenough A, et al.; for the United Kingdom Oscillation Study Group. High frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 2002;347:633-42
- Jobe AH, Bancalari E. NICHD/NHLSI/ORD workshop summary: bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9
- Rojas MA, Gonzalez A, Bancalari E, et al. Changing trends in the epidemiology and pathogenesis of chronic lung disease. J Pediatr 1995;126:605-10
- Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in post surfactant bronchopulmonary dysplasia. Hum Pathol 1998;29:710-7
- Tang J-R, Markham NE, Lin L-J, et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004;287:L344-51
- Jakkula M, Le Cras TD, Gebb S, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L600-7
- Le Cras TD, Markham NE, Tuder RM, et al. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 2002;283:L555-62
- Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4
- Bhatt AJ, Pryhuber GS, Huyck H, et al. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164:1971-80
- Greenough A, Alexander J, Burgess S, et al. Home oxygen status on rehospitalisation and primary care requirements of chronic lung disease infants. Arch Dis Child 2002;86:40-3
- Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89:673-8
- Baraldi E, Filippone M, Trevisanuto D, et al. Pulmonary function until two years of life in infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997;155:149-55
- Filippone M, Sartor M, Zachello F, Baraldi E. Flow limitation in infants with bronchopulmonary dysplasia and respiratory function at school age. Lancet 2003;361:753-4
- Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline membrane disease. N Engl J Med 1967;276:357-68
- Howlett A, Ohlsson A. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2003;4:CD000366
- Ng GY, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001;2:CD003214
- Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002;1:CD001817
- Brion LP, Primhak RA. Intravenous or eneteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2000;4:CD001453
- Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2006;2:CD001694
- Wang EEL, Ohlsson A, Kellner JD. Association of ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a meta-analysis. J Pediatr 1995;127:640-4
- Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev 2003;4:CD003744
- Baier RJ, Loggins J, Kruger TE. Failure of erythromycin to eliminate airway colonization with ureaplasma urealyticum in very low birth weight infants. BMC Pediatr 2003;3:10
- Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001146
- Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001144
- Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001145
- Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005;115:655-61
- Doyle LW, Davis PG, Morley CJ, et al. Low dose dexamethasone facilitates extubation among chronically ventilator dependent infants: a multicentre, international, randomized controlled trial. Pediatrics 2006;117:75-83
- Doyle LW, Davis PG, Morley CJ, et al. Outcome at two years of age of infants from the DART study: a multicentre, international, randomized controlled trial of low dose dexamethasone. Pediatrics 2007;119:716-21
- Shah SS, Ohlsson A, Halliday H, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birthweight preterm infants. Cochrane Database Syst Rev 2007;4:CD001969
- Watterburg KL, Gerdes JS, Gillford KL, et al. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104:1649-57
- Watterburg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114:1649-57
- Bonsante F, Latorre G, Iacobelli S, et al. Early low dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 2007;91:217-21
- Ng GY, Ohlsson A. Cromolyn sodium for the prevention of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001;1:CD003059
- Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007;4:CD000501
- Hallman M, Haataja K. Genetic influences and neonatal lung disease. Semin Neonatol 2003;8:19-27
- Kraybill EN, Runyan DK, Bose CL, et al. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams. J Pediatr 1989;115:115-20
- Bjorklund LJ, Ingimarsson J, Curstedt T, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lungs. Pediatr Res 1997;42:348-55
- Gonzalez A, Sosenko IRS, Chandar J, et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 g or less. J Pediatr 1996;128:470-8
- Watterberg KL, Demers LM, Scott SM, et al. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:210-5
- Van Marter LJ, Ammann O, Allred EN, et al. Chorioamnionitis, mechanical ventilation and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr 2002;140:171-6
- Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-9
- Padmanabhan R, Gudapaty R, Liener I, et al. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am J Respir Dis 1985;132:164-7
- Davis JM, Rosenfeld W, Richter SE, et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997;100:24-30
- Davis JM, Parad RB, Michele T, et al.; for the North American Recombinant Human CuZnSOD Study Group. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003;111:469-76
- Jain A, Madsen DC, Auld PA, et al. L-2 oxothiazolidine-4-carboxylate, a cysteine precursor stimulates growth and normalises tissue glutathione concentrations in rats fed a sulphur amino acid deficient diet. J Nutr 1995;125:851-6
- Frank L, Sosenko IR. Prenatal development of lung antioxidant enzymes in four species. J Pediatr 1987;110:106-6
- Cotgreave I, Moldeus P, Schuppe I. The metabolism of N-acetyl-cysteine by human endothelial cells. Biochem Pharmacol 1991;42:13-6
- Ahola T, Lapatto R, Raivio KO, et al. N-acetylcyteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr 2003;143:713-9
- Sandberg K, Fellman V, Stigson L, et al. N-acetylcytsteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate 2004;86:275-9
- Russell GA, Cooke RW. Randomised controlled trial of allopurinol prophylaxis in very preterm infants. Arch Dis Child Fetal Neonatal Ed 1995;73:F27-31
- Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004;36:1-9
- Gitto E, Reiter RJ, Sabatino G, et al. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J Pineal Res 2005;39:287-93
- Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003;4:CD003665
- Hazinski TA, France M, Kennedy KA, Hansen TN. Cimetidine reduces hyperoxic lung injury in lambs. J Appl Physiol 1989;67:2586-92
- Hazinski TA, Noisin E, Hamon I, DeMatteo A. Sheep lung cytochrome P450IAi (Cyp IaI):cDNA cloning and transcriptional regulation by oxygen tension. J Clin Invest 1995;96:2083-9
- Cotton RB, Hazinski TA, Morrow JD, et al. Cimetidine does not prevent lung injury in newborn premature infants. Pediatr Res 2006;59:795-800
- Merritt TA, Cochrane CG, Holcomb K, et al. Elastase and ∝1-proteinase inhibitor activity in tracheal aspirates: role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest 1983;72:656-66
- Stiskal JA, Dunn MS, Shennan AT, et al. ∝1-Proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. Pediatrics 1998;101:89-94
- Rosenfeld W, Concepcion L, Evans H, et al. Serial trypsin inhibitory capacity and ceruloplasmin levels in prematures at risk for bronchopulmonary dysplasia. Am Rev Respir Dis 1986;134:1229-32
- Friedholm BB. Astra Award Lecture: adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 1995;76:93-101
- Thurston JH, Hautiard RE, Dirgo JA. Aminophylline increases cerebral metabolic rate and decreased anoxic survival in young mice. Science 1978;201:649-51
- Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112
- Schmidt B, Roberts RS, Davis P, et al. Long term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357:1893
- Currie MS, Rao KM, Padmanabhan J, et al. Stimulus specific effects of pentoxifylline on neutrophils CR3 expression, degranulation, and superoxide production. J Leukoc Biol 1990;47:244-50
- Roberts PJ, Yog KL, Khwaja A, et al. Pentoxifylline at clinically achievable levels inhibits FMLP induced neutrophil responses, but not priming, upregulation, cell-adhesion molecules, or emigration induced by GM-CSF. Eur J Haemat 1993;22:371-82
- Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-αproduction from human alveolar macrophages. Am J Respir Crit Care Med 1999;159:508-11
- Poulakis N. Androutsos G, Kazi D, et al. The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications. Respir Med 1999;93:52-7
- Little S, Dean T, Bevin S, et al. Role of elevated plasma soluble ICAM-1 and bronchial lavage fluid IL-8 levels as markers of chronic lung disease in premature infants. Thorax 1995;50:1073-9
- ter Horst SA, Wagenaar GT, de Boer E, et al. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 2004;97:2014-9
- Lauterbach R, Szymura-Oleksiak J. Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia. Eur J Pediatr 1999;158:607
- Lauterbach R, Szymura-Oleksiak J, Pawlik D, et al. Nebulised pentoxifylline for prevention of bronchopulmonary dysplasia in very low birthweight infants: a pilot clinical study. J Matern Fetal Neonatal Med 2006;19:433-48
- Ballard HO, Bernard P, Qualls J, et al. Azithromycin protects against hyperoxic lung injury in neonatal rats. J Invest Med 2007;55:299-305
- Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 2007;62:483-8
- Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 2007;8:41
- Massaro GD, Mortola JP, Massaro D. Estrogen modulates the dimensions of the lung's gas exchange surface area and alveoli in female rats. Am J Physiol 1996;270:L110-4
- Trotter A, Ebsen M, Kiossis E, et al. Prenatal estrogen and progesterone deprivation impairs alveolar formation and fluid clearance in newborn piglets. Pediatr Res 2006;60:60-4
- Trotter A, Maier L, Kron M, Pohlandt F. Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed 2007;92:F94-8
- Smith LM, Leake RD, Berman N, et al. Postnatal thyroxine supplementation in infants less than 32 weeks'gestation: effects of pulmonary morbidity. J Perinatol 2000;20:427-31
- Kinsella JP, Abman SH. Inhaled nitric oxide in the premature newborn. J Pediatr 2007;151:10-5
- Balasubramaniam V, Tang JR, Maxey A, Plopper CG, Agman SH. Mild hypoxia inhibits alveolarisation in the endotracheal nitric oxide deficient mouse. Am Physiol Lung Cell Mol Physiol 2003;284:L964-71
- Kinsella JP, Parker TA, Galan H, et al. Effects of inhaled nitric oxide on pulmonary oedema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 1997;41:457-63
- Barrington KJ, Finer NN. Inhaled nitric oxide for preterm infants: a systemic review. Pediatrics 2007;120:1088-99
- Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006;355:343-53
- Schreiber MD, Gin-Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with respiratory distress syndrome. N Engl J Med 2003;349:2099-107
- Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006;355:354-64
- Auten RL, Mason SN, Whorton MH, et al. Inhaled ethyl nitrite prevents hyperoxia impaired postnatal alveolar development in newborn rats. Am J Respir Crit Care Med 2007;176:291-9
- Moya MP, Gow AJ, McMahon TJ, et al. S-nitrosothiol repletion by an inhaled gas regulates pulmonary function. Proc Nat Acad Sci USA 2001;98:5792-7
- Willet KE, Jobe AH, Ikegami M, et al. Antenatal endotoxin and glucocorticoid effects on lung morphometry in preterm lambs. Pediatr Res 2000;48:782-8
- Jobe AH. Antenatal factors and the development of bronchopulmonary dysplasia. Sem Neonatol 2003;8:9-17
- Kallapur SG, Kramer BW, Moss TJ, et al. Maternal glucocorticoids increase endotoxin-induced lung inflammation in preterm lambs. Am J Physiol Lung Cell Mol Physiol 2003;284:L633-42